Bristol-Myers Squibb Company revenue growth has been varied year-over-year.

What is BMY's revenue growth rate?

Historical revenue data is available for Bristol-Myers Squibb Company to analyze growth trends.

How fast is BMY earnings growing?

Earnings growth data is available for Bristol-Myers Squibb Company analysis.

What is BMY's profit margin?

Profit margin data is available for Bristol-Myers Squibb Company.

BMY Revenue & Earnings Growth Analysis 2026 - Is Bristol-Myers Squibb Company Growing?

Growth Summary

Bristol-Myers Squibb Company (BMY) has experienced challenges in growth. The company operates in the Healthcare sector, specifically in the Drug Manufacturers - General industry.

Over the past 4 years, Bristol-Myers Squibb Company has achieved a revenue compound annual growth rate (CAGR) of 1.0%, while earnings have grown at 0.2% CAGR.

Latest Revenue

$48.19B

Net Income

$7.05B

5-Year Revenue CAGR

1.0%

4 years of data

Net Margin

N/A

Latest period

Revenue Growth Over Time

Historical revenue and profitability trends for Bristol-Myers Squibb Company

The chart above illustrates Bristol-Myers Squibb Company's revenue trajectory over the past 4 years. The revenue pattern shows the challenges the company has faced in recent periods.

Year-over-Year Growth Rates

Annual percentage change in revenue and earnings

Growth rates provide insight into the momentum of Bristol-Myers Squibb Company's business.

Profit Margin Trends

How efficiently Bristol-Myers Squibb Company converts revenue into profit

Understanding Profit Margins

Profit margins reveal how much of each dollar of revenue Bristol-Myers Squibb Company retains at different stages:

Gross Margin (N/A%): What remains after direct production costs
Operating Margin (N/A%): Profit from core operations before interest and taxes
Net Margin (N/A%): Final profit after all expenses

Future Growth Outlook

Analyst estimates and forward-looking indicators

EPS Estimate 2026

$6.27

Current: $3.47

EPS Estimate 2027

$6.13

-2.3% expected growth

Price Target

$62.16

Analyst consensus

What Analysts Are Saying

Wall Street analysts project Bristol-Myers Squibb Company to continue focusing on sustainable operations. The consensus analyst rating is 3.3704 based on 27 analysts.

Growth Analysis Conclusion

Based on our comprehensive analysis, Bristol-Myers Squibb Company (BMY) demonstrates declining growth characteristics.

Key Takeaways:

Revenue Growth:, 1.0% CAGR over 4 years
Profitability: demonstrates the company is profitable
Efficiency:

Investment Considerations

This growth analysis provides a comprehensive view of Bristol-Myers Squibb Company's historical performance and future outlook. Investors should consider these growth metrics alongside valuation, competitive positioning, and broader market conditions when making investment decisions. Past performance does not guarantee future results.